http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2714875-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eb9c6b40161bafe7bd55f0b4defcea04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8073450a491d200d05b09b9beb6f0ec6 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y207-11024 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4184 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-1205 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4184 |
| filingDate | 2011-03-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-05-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fae83cd261c326a7a6752d93936acca8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c702c3bd44df65db4ab52a7004e4f0cd |
| publicationDate | 2019-05-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2714875-T3 |
| titleOfInvention | Methods of diagnosis and treatment of cancer in patients presenting or developing resistance to a first cancer therapy |
| abstract | Identification method of a subject with cancer who is likely to benefit from treatment with a combination therapy with a RAF inhibitor and a second inhibitor, in which the subject has cancer cells comprising a B-RAFV600E mutation, comprising the method: (a) test the gene copy number, mRNA level or a protein or phosphorylation of one or more kinase targets selected from the group consisting of MAP3K8 (TPL2 / COT), CRKL (CrkL), FGR (Fgr), PRKCE (Prkce), PRKCH (Prkch), ERBB2 (ErbB2), AXL (Axl), or PAK3 (Pak3) in cancer cells obtained from the subject and compare the gene copy number, mRNA level or the protein or phosphorylation with a gene copy number, a level of mRNA or a protein or phosphorylation of the target kinase in cells obtained from a subject without cancer, and (b) correlate the increased gene copy number or an alteration of mRNA expression or overexpression Protein or phosphorylation of the target kinase in cancer cells with respect to the subject's cells without cancer, with the subject with cancer likely to benefit from the combination therapy treatment. |
| priorityDate | 2010-03-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 123.